Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Despite yielding encouraging response rates, adding decitabine and vorinostat to chemo is not feasible for relapsed or refractory B-ALL because of a high incidence of significant toxicities.
Despite yielding encouraging response rates, adding decitabine and vorinostat to chemo is not feasible for relapsed or refractory B-ALL because of a high incidence of significant toxicities.
The FDA has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.
The FDA has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.
Results from a phase 2 study demonstrate the efficacy and manageable safety of nilotinib for the treatment of pediatric patients with Ph-positive CML in chronic phase.
Results from a phase 2 study demonstrate the efficacy and manageable safety of nilotinib for the treatment of pediatric patients with Ph-positive CML in chronic phase.
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
